June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Protective effects of a HIF Inhibitor halofuginone on light-induced retinal damage via suppression of HIF/BNIP3 axis
Author Affiliations & Notes
  • Yukihiro Miwa
    ophthalmology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
    Aichi animal eye clinic, Nagoya, Aichi, Japan
  • Chiho Shoda
    ophthalmology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
    ophthalmology, Nihon Daigaku, Chiyoda-ku, Tokyo, Japan
  • Deokho Lee
    ophthalmology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
  • Kazuno Negishi
    ophthalmology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
  • Toshihide Kurihara
    ophthalmology, Keio Gijuku Daigaku Igakubu Daigakuin Igaku Kenkyuka, Shinjuku-ku, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Yukihiro Miwa None; Chiho Shoda None; Deokho Lee None; Kazuno Negishi SEED Co., Ltd., Code F (Financial Support); Toshihide Kurihara SEED Co., Ltd., ROHTO Pharmaceutical Co., Ltd., Fuji Xerox Co., Ltd., Kowa Company, Limited, Tsubota Laboratory, Inc., Santen Pharmaceutical Co., Ltd., WAKASA SEIKATSU Co., Ltd, Code F (Financial Support)
  • Footnotes
    Support  Ministry of Education, Culture, Sports, Science and Technology (MEXT): 20K18393
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 664 – F0118. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yukihiro Miwa, Chiho Shoda, Deokho Lee, Kazuno Negishi, Toshihide Kurihara; Protective effects of a HIF Inhibitor halofuginone on light-induced retinal damage via suppression of HIF/BNIP3 axis. Invest. Ophthalmol. Vis. Sci. 2022;63(7):664 – F0118.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinal degenerative diseases cause progressive and irreversible visual impairment while effective therapies are still not available. Hypoxia-inducible factors (HIFs) are transcriptional factors that regulate angiogenesis, erythropoiesis, intracellular metabolism, and programmed cell death mainly depending on oxygen availability. In this study, we investigated the therapeutic effects of halofuginone (HF) focussing on HIFs and its target gene BNIP3 in a murine model of light-induced retinopathy (LIR).

Methods : The HIF inhibitory effect of HF on CoCl2-induced HIF activity was confirmed by Luciferase assay and qPCR using a 661W cell line. Eight-week-old male BALB/c mice were exposed to white LED light (3000 Lux) for 1 hour to create an LIR model. Neural retinas were harvested from LIR-treated mice, and qPCR and WB were performed to confirm the expression of HIF-1α and BNIP3. Mice were divided into HF group (0.4 mg/kg/day) and PBS group, and HF or PBS was administered 5 times in total before light exposure. Electroretinography (ERG) and Optical Coherence Tomography (OCT) were performed 7 days after light exposure. TUNEL staining was performed on the retinas of LIR model mice treated with HF or PBS.

Results : Luciferase assay and qPCR using 661W cell line showed that HF significantly suppressed the expression of HIF in a concentration-dependent manner. Light exposure significantly increased the expression of HIF-1α (qPCR: 1.9-fold, p < 0.001; WB: 2.9-fold, p < 0.01) and BNIP3 (qPCR: 1.3-fold, p < 0.05; WB: 1.3-fold, p < 0.05) in the retina. OCT results showed a significant inhibitory effect of HF on the retinal damage. TUNEL staining showed an inhibitory effect of HF on apoptosis of photoreceptors.

Conclusions : This study suggests the possibility of therapeutic effects of HF on retinal degeneration via the HIF/BNIP3 axis.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×